HR and breast carcinoma: In Module 2A, 31 patients with post-CDK4/6 inhibitor HR+/HER2− advanced breast cancer received samuraciclib in combination with fulvestrant: 6 at 240 mg OD and 25 at 360 mg OD of samuraciclib (Supplementary Fig. 1).